RTTNews | Jun 28, 2021 08:29AM EDT

08:28 Monday, June 28, 2021 (RTTNews.com) - Eiger BioPharmaceuticals, Inc. (EIGR) announced a presentation of positive phase 2 study results of Avexitide in congenital hyperinsulinism. Avexitide infusion demonstrated significant reductions in glucose infusion requirements to maintain euglycemia or normal glucose levels in neonates and infants. Avexitide represents a promising, targeted approach for the treatment of congenital hyperinsulinism.

Avexitide is a targeted, first-in-class, GLP-1 antagonist in development for the treatment of hyperinsulinism, an ultra-rare, life-threatening, pediatric disorder of persistent hypoglycemia that results in irreversible brain damage in up to 50% of children.

Avexitide 100, 200 and 1,000 pmol/kg/min ascending doses demonstrated 1.3 (15%), 2.9 (24%), and 4.3 (56%) mg/kg/min reductions in glucose infusion rate relative to placebo, respectively, and entirely abolished the glucose requirement in 50% of patients at the top dose.

Avexitide was well-tolerated in this study. Adverse events were typically mild in severity and transient, and there were no serious adverse events.

Read the original article on RTTNews ( https://www.rttnews.com/3205404/eiger-announces-positive-phase-2-results-of-avexitide-in-congenital-hyperinsulinism.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved